Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Food Labeling; Notification Procedures for Statements on Dietary Supplements, 25282-25283 [2019-11419]

Download as PDF 25282 Federal Register / Vol. 84, No. 105 / Friday, May 31, 2019 / Notices events/improving-implementation-riskbased-monitoring-approaches-clinicaltrials. Transcripts: Please be advised that transcripts of the public workshop will not be available. Dated: May 28, 2019. Lowell J. Schiller, Principal Associate Commissioner for Policy. [FR Doc. 2019–11411 Filed 5–30–19; 8:45 am] BILLING CODE 4164–01–P Food and Drug Administration [Docket No. FDA–2013–N–0032] Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Food Labeling; Notification Procedures for Statements on Dietary Supplements Food and Drug Administration, HHS. ACTION: Domini Bean, Office of Operations, Food and Drug Administration, Three White Flint North, 10A–12M, 11601 Landsdown St., North Bethesda, MD 20852, 301–796–5733, PRAStaff@ fda.hhs.gov. SUPPLEMENTARY INFORMATION: In compliance with 44 U.S.C. 3507, FDA has submitted the following proposed collection of information to OMB for review and clearance. Food Labeling; Notification Procedures for Statements on Dietary Supplements—21 CFR 101.93 DEPARTMENT OF HEALTH AND HUMAN SERVICES AGENCY: FOR FURTHER INFORMATION CONTACT: Notice. The Food and Drug Administration (FDA or we) is announcing that a proposed collection of information has been submitted to the Office of Management and Budget (OMB) for review and clearance under the Paperwork Reduction Act of 1995. DATES: Fax written comments on the collection of information by July 1, 2019. SUMMARY: To ensure that comments on the information collection are received, OMB recommends that written comments be faxed to the Office of Information and Regulatory Affairs, OMB, Attn: FDA Desk Officer, Fax: 202– 395–7285, or emailed to oira_ submission@omb.eop.gov. All comments should be identified with the OMB control number 0910–0331. Also include the FDA docket number found in brackets in the heading of this document. ADDRESSES: OMB Control Number 0910–0331— Extension Section 403(r)(6) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) (21 U.S.C. 343(r)(6)) and § 101.93 (21 CFR 101.93) of our regulations require that, no later than 30 days after the first marketing, we be notified by the manufacturer, packer, or distributor of a dietary supplement that it is marketing a dietary supplement product that bears on its label or in its labeling a statement provided for in section 403(r)(6) of the FD&C Act. In accordance with these requirements, submissions must include: (1) The name and address of the manufacturer, packer, or distributor of the dietary supplement product; (2) the text of the statement that is being made; (3) the name of the dietary ingredient or supplement that is the subject of the statement; (4) the name of the dietary supplement (including the brand name); and (5) the signature of a responsible individual or the person who can certify the accuracy of the information presented, and who must certify that the information contained in the notice is complete and accurate, and that the notifying firm has substantiation that the statement is truthful and not misleading. Our electronic form (Form FDA 3955) allows respondents to the information collection to electronically submit notifications to FDA via an electronic system. We are upgrading our current system (the FDA Unified Registration Listing System known as FURLS) to deploy the Food Applications Regulatory Management (FARM) system. FARM is modeled after FURLS and collects the same information, but improves our operational efficiency. A web link of the FARM system can be found here: https://www.fda.gov/Food/ DietarySupplements/IndustryInfo/ ucm485532.htm. Firms that prefer to submit a paper notification in a format of their own choosing still have the option to do so; however, Form FDA 3955 prompts respondents to include certain elements in their structure/ function claim notification (SFCN) described in § 101.93 in a standard electronic format and helps respondents organize their SFCN to include only the information needed for our review of the claim. Note that the SFCN, whether electronic or paper, is used for all claims made pursuant to section 403(r)(6) of the FD&C Act, including nutrient deficiency claims and general well-being claims in addition to structure/function claims. The electronic form, and any optional elements prepared as attachments to the form (e.g., label), can be submitted in electronic format. Submissions of SFCNs will continue to be allowed in paper format. We use this information to evaluate whether statements made for dietary ingredients or dietary supplements are permissible under section 403(r)(6) of the FD&C Act. In the Federal Register of February 7, 2019 (84 FR 2528), we published a 60day notice requesting public comment on the proposed collection of information. No comments were received. Description of Respondents: Respondents to this collection of information include manufacturers, packers, or distributors of dietary supplements that bear section 403(r)(6) of the FD&C Act statements on their labels or labeling. We estimate the burden of this collection of information as follows: TABLE 1—ESTIMATED ANNUAL REPORTING BURDEN 1 khammond on DSKBBV9HB2PROD with NOTICES 101.93 ............................................... 1 There Number of responses per respondent Number of respondents 21 CFR Section 3,690 Total annual responses 1 3,690 Average burden per response 0.75 (45 minutes) ............................. Total hours 2,767.5 are no capital costs or operating and maintenance costs associated with this collection of information. Our burden estimate reflects an overall increase of 1,117.5 hours (from 1,650 hours) and a corresponding increase of 1,490 responses (from 2,200 VerDate Sep<11>2014 16:42 May 30, 2019 Jkt 247001 responses). We attribute this adjustment to an increase in the average number of notification submissions we received over the preceding 12 months, which PO 00000 Frm 00052 Fmt 4703 Sfmt 4703 we expect will continue over the next 3 years. We believe gathering information to satisfy the notification requirements of section 403(r)(6) of the FD&C Act by E:\FR\FM\31MYN1.SGM 31MYN1 Federal Register / Vol. 84, No. 105 / Friday, May 31, 2019 / Notices submitting information regarding section 403(r)(6) of the FD&C Act statements on labels or in labeling of dietary supplements imposes minimal burden on respondents. We expect the information needed is immediately available to the manufacturer, packer, or distributor of the dietary supplement that bears such a statement on its label or in its labeling. We believe also that submission via the FARM system will facilitate reporting for respondents. We estimate that, each year, approximately 3,690 firms will submit the information required by section 403(r)(6) of the FD&C Act. Assuming firms require 0.75 hour to gather the information needed and prepare a communication, we calculate a total of 2,767.5 hours (3,690 total annual responses × 0.75 hour). Notice; establishment of a public docket; request for comments. Electronic Submissions Submit electronic comments in the following way: • Federal eRulemaking Portal: https://www.regulations.gov. Follow the instructions for submitting comments. Comments submitted electronically, including attachments, to https:// www.regulations.gov will be posted to the docket unchanged. Because your comment will be made public, you are solely responsible for ensuring that your comment does not include any confidential information that you or a third party may not wish to be posted, such as medical information, your or anyone else’s Social Security number, or confidential business information, such as a manufacturing process. Please note that if you include your name, contact information, or other information that identifies you in the body of your comments, that information will be posted on https://www.regulations.gov. • If you want to submit a comment with confidential information that you do not wish to be made available to the public, submit the comment as a written/paper submission and in the manner detailed (see ‘‘Written/Paper Submissions’’ and ‘‘Instructions’’). The Food and Drug Administration (FDA or the Agency) is announcing the establishment of a docket to solicit public comment on a potential modification to the Opioid Analgesic Risk Evaluation and Mitigation Strategy (OA REMS) to require that certain solid, oral dosage forms of immediate-release (IR) opioid analgesics commonly prescribed for treatment of acute pain be made available in fixed-quantity unit-of-use blister packaging for outpatient dispensing. This could reduce the amount of unused opioid analgesics, thereby reducing opportunities for misuse, abuse, inappropriate access, and overdose, and possibly reducing the development of new opioid addiction. DATES: Submit either electronic or written comments by July 30, 2019. ADDRESSES: You may submit comments as follows. Please note that late, Written/Paper Submissions Submit written/paper submissions as follows: • Mail/Hand Delivery/Courier (for written/paper submissions): Dockets Management Staff (HFA–305), Food and Drug Administration, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852. • For written/paper comments submitted to the Dockets Management Staff, FDA will post your comment, as well as any attachments, except for information submitted, marked and identified, as confidential, if submitted as detailed in ‘‘Instructions.’’ Instructions: All submissions received must include the Docket No. FDA– 2019–N–1845 for ‘‘Fixed-Quantity Unitof-Use Blister Packaging for Certain Immediate-Release Opioid Analgesics for Treatment of Acute Pain; Establishment of a Public Docket; Request for Comments.’’ Received Dated: May 28, 2019. Lowell J. Schiller, Principal Associate Commissioner for Policy. [FR Doc. 2019–11419 Filed 5–30–19; 8:45 am] BILLING CODE 4164–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration [Docket No. FDA–2019–N–1845] Fixed-Quantity Unit-of-Use Blister Packaging for Certain ImmediateRelease Opioid Analgesics for Treatment of Acute Pain; Establishment of a Public Docket; Request for Comments AGENCY: Food and Drug Administration, HHS. ACTION: SUMMARY: khammond on DSKBBV9HB2PROD with NOTICES untimely filed comments will not be considered. Electronic comments must be submitted on or before July 30, 2019. The https://www.regulations.gov electronic filing system will accept comments until 11:59 p.m. Eastern Time at the end of July 30, 2019. Comments received by mail/hand delivery/courier (for written/paper submissions) will be considered timely if they are postmarked or the delivery service acceptance receipt is on or before that date. VerDate Sep<11>2014 16:42 May 30, 2019 Jkt 247001 PO 00000 Frm 00053 Fmt 4703 Sfmt 4703 25283 comments, those filed in a timely manner (see ADDRESSES), will be placed in the docket and, except for those submitted as ‘‘Confidential Submissions,’’ publicly viewable at https://www.regulations.gov or at the Dockets Management Staff between 9 a.m. and 4 p.m., Monday through Friday. • Confidential Submissions—To submit a comment with confidential information that you do not wish to be made publicly available, submit your comments only as a written/paper submission. You should submit two copies total. One copy will include the information you claim to be confidential with a heading or cover note that states ‘‘THIS DOCUMENT CONTAINS CONFIDENTIAL INFORMATION.’’ The Agency will review this copy, including the claimed confidential information, in its consideration of comments. The second copy, which will have the claimed confidential information redacted/blacked out, will be available for public viewing and posted on https://www.regulations.gov. Submit both copies to the Dockets Management Staff. If you do not wish your name and contact information to be made publicly available, you can provide this information on the cover sheet and not in the body of your comments and you must identify this information as ‘‘confidential.’’ Any information marked as ‘‘confidential’’ will not be disclosed except in accordance with 21 CFR 10.20 and other applicable disclosure law. For more information about FDA’s posting of comments to public dockets, see 80 FR 56469, September 18, 2015, or access the information at: https://www.gpo.gov/ fdsys/pkg/FR-2015-09-18/pdf/201523389.pdf. Docket: For access to the docket to read background documents or the electronic and written/paper comments received, go to https:// www.regulations.gov and insert the docket number, found in brackets in the heading of this document, into the ‘‘Search’’ box and follow the prompts and/or go to the Dockets Management Staff, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852. FOR FURTHER INFORMATION CONTACT: Patrick Raulerson, Center for Drug Evaluation and Research, Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 51, Rm. 6260, Silver Spring, MD 20993, 301–796– 3522, Patrick.Raulerson@fda.hhs.gov. SUPPLEMENTARY INFORMATION: I. Background In 2017, opioid-involved overdoses killed more than 47,000 people, with E:\FR\FM\31MYN1.SGM 31MYN1

Agencies

[Federal Register Volume 84, Number 105 (Friday, May 31, 2019)]
[Notices]
[Pages 25282-25283]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2019-11419]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. FDA-2013-N-0032]


Agency Information Collection Activities; Submission for Office 
of Management and Budget Review; Comment Request; Food Labeling; 
Notification Procedures for Statements on Dietary Supplements

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: The Food and Drug Administration (FDA or we) is announcing 
that a proposed collection of information has been submitted to the 
Office of Management and Budget (OMB) for review and clearance under 
the Paperwork Reduction Act of 1995.

DATES: Fax written comments on the collection of information by July 1, 
2019.

ADDRESSES: To ensure that comments on the information collection are 
received, OMB recommends that written comments be faxed to the Office 
of Information and Regulatory Affairs, OMB, Attn: FDA Desk Officer, 
Fax: 202-395-7285, or emailed to [email protected]. All 
comments should be identified with the OMB control number 0910-0331. 
Also include the FDA docket number found in brackets in the heading of 
this document.

FOR FURTHER INFORMATION CONTACT: Domini Bean, Office of Operations, 
Food and Drug Administration, Three White Flint North, 10A-12M, 11601 
Landsdown St., North Bethesda, MD 20852, 301-796-5733, 
[email protected].

SUPPLEMENTARY INFORMATION: In compliance with 44 U.S.C. 3507, FDA has 
submitted the following proposed collection of information to OMB for 
review and clearance.

Food Labeling; Notification Procedures for Statements on Dietary 
Supplements--21 CFR 101.93

OMB Control Number 0910-0331--Extension

    Section 403(r)(6) of the Federal Food, Drug, and Cosmetic Act (FD&C 
Act) (21 U.S.C. 343(r)(6)) and Sec.  101.93 (21 CFR 101.93) of our 
regulations require that, no later than 30 days after the first 
marketing, we be notified by the manufacturer, packer, or distributor 
of a dietary supplement that it is marketing a dietary supplement 
product that bears on its label or in its labeling a statement provided 
for in section 403(r)(6) of the FD&C Act. In accordance with these 
requirements, submissions must include: (1) The name and address of the 
manufacturer, packer, or distributor of the dietary supplement product; 
(2) the text of the statement that is being made; (3) the name of the 
dietary ingredient or supplement that is the subject of the statement; 
(4) the name of the dietary supplement (including the brand name); and 
(5) the signature of a responsible individual or the person who can 
certify the accuracy of the information presented, and who must certify 
that the information contained in the notice is complete and accurate, 
and that the notifying firm has substantiation that the statement is 
truthful and not misleading.
    Our electronic form (Form FDA 3955) allows respondents to the 
information collection to electronically submit notifications to FDA 
via an electronic system. We are upgrading our current system (the FDA 
Unified Registration Listing System known as FURLS) to deploy the Food 
Applications Regulatory Management (FARM) system. FARM is modeled after 
FURLS and collects the same information, but improves our operational 
efficiency. A web link of the FARM system can be found here: https://www.fda.gov/Food/DietarySupplements/IndustryInfo/ucm485532.htm. Firms 
that prefer to submit a paper notification in a format of their own 
choosing still have the option to do so; however, Form FDA 3955 prompts 
respondents to include certain elements in their structure/function 
claim notification (SFCN) described in Sec.  101.93 in a standard 
electronic format and helps respondents organize their SFCN to include 
only the information needed for our review of the claim. Note that the 
SFCN, whether electronic or paper, is used for all claims made pursuant 
to section 403(r)(6) of the FD&C Act, including nutrient deficiency 
claims and general well-being claims in addition to structure/function 
claims. The electronic form, and any optional elements prepared as 
attachments to the form (e.g., label), can be submitted in electronic 
format. Submissions of SFCNs will continue to be allowed in paper 
format. We use this information to evaluate whether statements made for 
dietary ingredients or dietary supplements are permissible under 
section 403(r)(6) of the FD&C Act.
    In the Federal Register of February 7, 2019 (84 FR 2528), we 
published a 60-day notice requesting public comment on the proposed 
collection of information. No comments were received.
    Description of Respondents: Respondents to this collection of 
information include manufacturers, packers, or distributors of dietary 
supplements that bear section 403(r)(6) of the FD&C Act statements on 
their labels or labeling.
    We estimate the burden of this collection of information as 
follows:

                                  Table 1--Estimated Annual Reporting Burden 1
----------------------------------------------------------------------------------------------------------------
                                                   Number of
        21 CFR Section             Number of     responses per   Total annual    Average burden     Total hours
                                  respondents     respondent       responses      per response
----------------------------------------------------------------------------------------------------------------
101.93........................           3,690               1           3,690  0.75 (45                 2,767.5
                                                                                 minutes).
----------------------------------------------------------------------------------------------------------------
\1\ There are no capital costs or operating and maintenance costs associated with this collection of
  information.

    Our burden estimate reflects an overall increase of 1,117.5 hours 
(from 1,650 hours) and a corresponding increase of 1,490 responses 
(from 2,200 responses). We attribute this adjustment to an increase in 
the average number of notification submissions we received over the 
preceding 12 months, which we expect will continue over the next 3 
years. We believe gathering information to satisfy the notification 
requirements of section 403(r)(6) of the FD&C Act by

[[Page 25283]]

submitting information regarding section 403(r)(6) of the FD&C Act 
statements on labels or in labeling of dietary supplements imposes 
minimal burden on respondents. We expect the information needed is 
immediately available to the manufacturer, packer, or distributor of 
the dietary supplement that bears such a statement on its label or in 
its labeling. We believe also that submission via the FARM system will 
facilitate reporting for respondents. We estimate that, each year, 
approximately 3,690 firms will submit the information required by 
section 403(r)(6) of the FD&C Act. Assuming firms require 0.75 hour to 
gather the information needed and prepare a communication, we calculate 
a total of 2,767.5 hours (3,690 total annual responses x 0.75 hour).

    Dated: May 28, 2019.
Lowell J. Schiller,
Principal Associate Commissioner for Policy.
[FR Doc. 2019-11419 Filed 5-30-19; 8:45 am]
BILLING CODE 4164-01-P


This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.